- Senate passes Drug Quality and Security Act
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- State of the market: Are generic drugs approaching their peak?
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
PHOENIX — Specialty pharmacy provider The Apothecary Shops has inked a deal with Pfizer to distribute a new drug for treating kidney cancer.
The specialty provider announced Wednesday that Pfizer had granted it distribution rights for Inlyta (axitinib), which the Food and Drug Administration approved on Jan. 27 for advanced renal cell carcinoma in patients who have failed one systemic therapy.
"The Apothecary Shops is excited to be included in the limited network of pharmacies managing Inlyta," The Apothecary Shops president Keith Cook said. "We have a first-class oncology team, and this announcement certainly reinforces our strong position in the oncology market."